Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: Acute phase reactant levels contribute separately to predicting outcome at one year

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Kay, Jonathan ^a   Morgacheva, Olga ^b   Messing, Susan P ^c   Kremer, Joel M ^d   Greenberg, Jeffrey D ^e   Reed, George W ^f   Gravallese, Ellen M ^a   Furst, Daniel E ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e NYU HOSPITAL FOR JOINT DISEASES   (United States)

^f The Consortium of Rheumatology Researchers of North America Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOOD; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; QUESTIONNAIRE; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84894065958     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4469     Document Type: Article

References (33)

1. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984, 43:8-17. 10.1136/ard.43.1.8, 1001208, 6696524.
2. Möttönen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988, 47:648-653. 10.1136/ard.47.8.648, 1006716, 3137902.
3. Dixey J, Solymossy C, Young A, Early RAS. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol Suppl 2004, 69:48-54.
4. Caruso I, Santandrea S, Sarzi Puttini P, Boccassini L, Montrone F, Cazzola M, Azzolini V, Segre D. Clinical, laboratory and radiographic features in early rheumatoid arthritis. J Rheumatol 1990, 17:1263-1267.
5. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998, 25:2108-2117.
6. van Leeuwen MA, van Rijswijk MH, van der Heijde DM, Te Meerman GJ, van Riel PL, Houtman PM, van De Putte LB, Limburg PC. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993, 32:9-13. 10.1093/rheumatology/32.suppl_3.9, 8508266.
7. Aman S, Paimela L, Leirisalo-Repo M, Risteli J, Kautiainen H, Helve T, Hakala M. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study. Rheumatology 2000, 39:1009-1013. 10.1093/rheumatology/39.9.1009, 10986307.
8. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:1473-1477. 10.1002/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N, 10902748.
9. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001, 60:924-927. 10.1136/ard.60.10.924, 1753390, 11557647.
10. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007, 27:793-806. 10.1007/s00296-007-0357-y, 17505829.
11. Jansen LM, van Schaardenburg D, van Der Horst-Bruinsma IE, Bezemer PD, Dijkmans BA. Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis 2000, 59:223-226. 10.1136/ard.59.3.223, 1753094, 10700432.
12. Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1977, 1:195-197. 10.1136/bmj.1.6055.195, 1604383, 832072.
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
14. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, Arthur V, Emery P. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1997, 24:9-13.
15. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009, 68:954-960. 10.1136/ard.2007.084459, 2674547, 18490431.
16. Foltz V, Gandjbakhch F, Etchepare F, Rosenberg C, Tanguy ML, Rozenberg S, Bourgeois P, Fautrel B. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum 2012, 64:67-76. 10.1002/art.33312, 21904998.
17. Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol 2009, 36:1606-1610. 10.3899/jrheum.081188, 19531760.
18. Gardiner PV, Bell AL, Taggart AJ, Wright G, Kee F, Smyth A, McKane R, Lee J, Rooney ME, Whitehead E. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:506-507. 1755401, 15708909.
19. Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009, 4:e6242. 10.1371/journal.pone.0006242, 2707000, 19606218.
20. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005, 52:3873-3879. 10.1002/art.21494, 16320335.
21. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003, 48:313-318. 10.1002/art.10817, 12571838.
22. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005, 7:R796-R806. 10.1186/ar1740, 1175030, 15987481.
23. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:S100-S108.
24. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202, 7362664.
25. Pincus T, Summey JA, Soraci SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983, 26:1346-1353. 10.1002/art.1780261107, 6639693.
26. Kremer J. The CORRONA database. Ann Rheum Dis 2005, 64:iv37-iv41. 1766903, 16239384.
27. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008, 58:2958-2967. 10.1002/art.23945, 18821687.
28. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207. 10.1056/NEJMoa0807646, 18997196, JUPITER Study Group.
29. Konttinen YT, Honkanen VE, Gronblad M, Keinonen M, Santavirta N, Santavirta S. The relation of extraarticular tenderness to inflammatory joint disease and personality in patients with rheumatoid arthritis. J Rheumatol 1992, 19:851-855.
30. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986, 29:822-831. 10.1002/art.1780290702, 3741499.
31. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 312:818-822. 10.1056/NEJM198503283121303, 3883172.
32. Bentley MJ. Development and evaluation of disease activity measures in rheumatoid arthritis using multi-level mixed modeling and other statistical methodologies: a dissertation. Dissertation, Doctoral 2010, University of Massachusetts Medical School, Graduate School of Biomedical Sciences.
33. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722-732. 10.1002/art.20878, 15751097.